Cargando…

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the immunomodulatory drug lenalidomide was clinically active with a good tolerability profile in the open-label, single-arm, phase II L-MIND study of patients with relapsed/refractory diffuse large B-cell l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duell, Johannes, Maddocks, Kami J., González-Barca, Eva, Jurczak, Wojciech, Liberati, Anna Marina, de Vos, Sven, Nagy, Zsolt, Obr, Aleš, Gaidano, Gianluca, Abrisqueta, Pau, Kalakonda, Nagesh, André, Marc, Dreyling, Martin, Menne, Tobias, Tournilhac, Olivier, Augustin, Marinela, Rosenwald, Andreas, Dirnberger-Hertweck, Maren, Weirather, Johannes, Ambarkhane, Sumeet, Salles, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409029/ https://www.ncbi.nlm.nih.gov/pubmed/34196165 http://dx.doi.org/10.3324/haematol.2020.275958

Ejemplares similares

P1138: FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L-MIND STUDY
por: Duell, Johannes, et al.
Publicado: (2023)

PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Duell, Johannes, et al.
Publicado: (2023)

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
por: Jurczak, W, et al.
Publicado: (2018)

A phase 2a, single‐arm, open‐label study of tafasitamab, a humanized, Fc‐modified, anti‐CD19 antibody, in patients with relapsed/refractory B‐precursor cell acute lymphoblastic leukemia
por: Klisovic, Rebecca B., et al.
Publicado: (2021)

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
por: Belada, David, et al.
Publicado: (2023)

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)

The use of tafasitamab in diffuse large B-cell lymphoma
por: Düll, Johannes, et al.
Publicado: (2021)

Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report
por: Jurczak, Wojciech, et al.
Publicado: (2016)

PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
por: Belada, D., et al.
Publicado: (2022)

Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis
por: Constantinescu, Cris S., et al.
Publicado: (2015)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison
por: Cordoba, Raul, et al.
Publicado: (2022)

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
por: Patra-Kneuer, Maria, et al.
Publicado: (2023)

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
por: Nowakowski, Grzegorz S., et al.
Publicado: (2022)

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2021)

Preclinical study of CD19 detection methods post tafasitamab treatment
por: Ilieva, Kristina, et al.
Publicado: (2023)

Zacualpan, Mor. : un estudio de relaciones sociales
por: Ramírez Melgarejo, Ramón
Publicado: (1976)

Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report
por: Nasir, Syed Alishan, et al.
Publicado: (2022)

Mors repentina, ensayos sobre la grandeza y la miseria del cuerpo /
por: González-Crussí, F.
Publicado: (2001)

Theoretical Study for Adsorption–Diffusion on H-MOR and Pyridine Pre-adsorbed H-MOR of Dimethyl Ether Carbonylation
por: Zhao, Jiabao, et al.
Publicado: (2023)

Role of efficacy as a determinant of locomotor activation by mu‐opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR‐selective phenylmorphans with high‐to‐low MOR efficacy
por: Santos, Edna J., et al.
Publicado: (2023)

RVX 208
Publicado: (2012)

Pityriasis lichenoides chronica in a patient on tafasitamab and lenalidomide therapy for diffuse large B-cell lymphoma
por: Roster, Katie, et al.
Publicado: (2023)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
por: Abdulhaq, Haifaa, et al.
Publicado: (2023)

Diferencía social, estudio de caso: Jaloxtoc, Mor.
por: Trujillo Santiesteban, María de Lourdes
Publicado: (1988)

Plume–MOR decoupling and the timing of India–Eurasia collision
por: Sehsah, Haytham, et al.
Publicado: (2022)

Synthesis of Hierarchical MOR-Type Zeolites with Improved Catalytic Properties
por: Mcheik, Zeinab, et al.
Publicado: (2021)

MOR promotes epithelial-mesenchymal transition and proliferation via PI3K/AKT signaling pathway in human colorectal cancer: MOR promotes EMT and proliferation
por: Gao, Lingling, et al.
Publicado: (2022)

Cantata no. 208 Was mir behagt : Hunt cantata /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1986)

Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy
por: Her, Jung Hyun, et al.
Publicado: (2022)

P1227: COMPREHENSIVE MOLECULAR SUBTYPING OF DIFFUSE LARGE B-CELL LYMPHOMA CELL LINES AND ASSOCIATION WITH TAFASITAMAB ACTIVITY
por: Arora, Arshi, et al.
Publicado: (2023)

Directed Flow in 158 A GeV $^{208}Pb$ + $^{208}Pb$ Collisions
por: Aggarwal, M.M., et al.
Publicado: (1998)

Particle production in 158.A GeV $^{208}$Pb + $^{208}$Pb collisions
por: Awes, T C
Publicado: (1999)

Compton scattering on $^{208}$Pb
por: Alberico, W M, et al.
Publicado: (1982)

Oral Presentations 208–237
Publicado: (2001)

Competition between Allowed and First-Forbidden $β$ Decay: The Case of $^{208}$Hg$→^{208}$Tl
por: Carroll, R J, et al.
Publicado: (2020)

Freeze-Out Parameters in Central 158 AGeV $^{208}Pb$ + $^{208}Pb$ Collisions
por: Aggarwal, M.M., et al.
Publicado: (1999)

Direct Photon Production in 158 A GeV $^{208}Pb+^{208}Pb$ collisions
por: Aggarwal, M.M., et al.
Publicado: (2001)

Direct Photon Production in 158 A GeV $^{208}$ PB+$^{208}$ PB Collisions
por: Peitzmann, Thomas
Publicado: (2001)

P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS
por: Rosenthal, Allison, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8ik0l0c956gk9qi1936qdsdm72